OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported full-year 2024 financial ...

Fintel reports that on April 2, 2025, Lake Street initiated coverage of OS Therapies (NYSEAM:OSTX) with a Buy recommendation. Analyst Price Forecast Suggests 865.16% Upside As of March 19, 2025, the ...

“2024 was a transformative year for OS Therapies as we completed our initial public offering and finalized the treatment phase of our Phase 2b clinical trial in the prevention of recurrence in ...

Dialogue open with FDA in preparation for End of Phase 2 Meeting request New canine elite responder biomarkers added to human biomarker strategy OS Therapies (NYSE-A: OSTX) (“OS Therapies” or ...

OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a regulatory update for its ...

Shares of OSTX opened at $1.54 on Monday. The company’s fifty day moving average is $1.89 and its 200-day moving average is $2.73. OS Therapies has a 12 month low of $1.41 and a 12 month high of ...

NEW YORK - OS Therapies (OSTX), a biopharmaceutical company specializing in clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) treatments, has announced progress with regulatory ...

NEW YORK - OS Therapies (OSTX), a biopharmaceutical company specializing in clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) treatments, has announced progress with regulatory agencies ...